Barings’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.07M Sell
1,162
-703
-38% -$713K 0.02% 136
2025
Q4
$2M Buy
1,865
+1,297
+228% +$1.24M 0.04% 110
2025
Q3
$433K Sell
568
-678
-54% -$505K 0.01% 148
2025
Q2
$971K Buy
1,246
+55
+5% +$42.7K 0.02% 133
2025
Q1
$984K Sell
1,191
-478
-29% -$398K 0.02% 131
2024
Q4
$1.29M Buy
1,669
+1,194
+251% +$989K 0.03% 121
2024
Q3
$421K Sell
475
-7
-1% -$6.29K 0.01% 142
2024
Q2
$436K Buy
+482
New +$386K 0.01% 133
2024
Q1
Sell
-561
Closed -$327K 163
2023
Q4
$327K Hold
561
0.01% 133
2023
Q3
$301K Sell
561
-21
-4% -$10.8K 0.01% 132
2023
Q2
$273K Buy
+582
New +$244K 0.01% 149
2023
Q1
Sell
-1,889
Closed -$691K 179
2022
Q4
$691K Sell
1,889
-474
-20% -$168K 0.02% 132
2022
Q3
$764K Sell
2,363
-2,171
-48% -$688K 0.03% 128
2022
Q2
$1.47M Buy
4,534
+1,929
+74% +$579K 0.05% 139
2022
Q1
$746K Sell
2,605
-109
-4% -$28.1K 0.02% 186
2021
Q4
$749K Sell
2,714
-65
-2% -$16.5K 0.02% 210
2021
Q3
$642K Sell
2,779
-1,748
-39% -$431K 0.01% 219
2021
Q2
$1.04M Sell
4,527
-537
-11% -$108K 0.02% 209
2021
Q1
$946K Sell
5,064
-647
-11% -$127K 0.02% 238
2020
Q4
$964K Sell
5,711
-52,445
-90% -$7.83M 0.02% 231
2020
Q3
$8.61M Sell
58,156
-13,912
-19% -$2.15M 0.2% 87
2020
Q2
$10M Hold
72,068
0.33% 58
2020
Q1
$10M Sell
72,068
-5,411
-7% -$743K 0.33% 58
2019
Q4
$10.2M Buy
77,479
+17,512
+29% +$2.03M 0.27% 67
2019
Q3
$6.71M Buy
59,967
+1,620
+3% +$180K 0.15% 130
2019
Q2
$6.46M Buy
58,347
+12,860
+28% +$1.51M 0.14% 140
2019
Q1
$5.9M Sell
45,487
-37,853
-45% -$4.6M 0.14% 126
2018
Q4
$9.64M Sell
83,340
-4,971
-6% -$555K 0.17% 96
2018
Q3
$9.48M Sell
88,311
-11,548
-12% -$1.15M 0.13% 120
2018
Q2
$8.52M Buy
99,859
+13,940
+16% +$1.14M 0.12% 128
2018
Q1
$6.65M Sell
85,919
-154
-0.2% -$12.4K 0.1% 154
2017
Q4
$7.27M Buy
86,073
+40,252
+88% +$3.42M 0.09% 157
2017
Q3
$3.92M Buy
45,821
+22,400
+96% +$1.84M 0.07% 176
2017
Q2
$1.93M Sell
23,421
-3,821
-14% -$312K 0.06% 317
2017
Q1
$2.29M Buy
27,242
+13,621
+100% +$1.09M 0.03% 554
2016
Q4
$1M Hold
13,621
0.03% 459
2016
Q3
$1.09M Hold
13,621
0.03% 419
2016
Q2
$1.07M Sell
13,621
-29,200
-68% -$2.2M 0.03% 466
2016
Q1
$3.08M Sell
42,821
-33,500
-44% -$2.53M 0.08% 181
2015
Q4
$6.43M Sell
76,321
-1,200
-2% -$99.6K 0.16% 73
2015
Q3
$6.49M Buy
77,521
+52,900
+215% +$4.47M 0.16% 74
2015
Q2
$2.06M Sell
24,621
-32,711
-57% -$2.49M 0.06% 314
2015
Q1
$4.17M Sell
57,332
-10,400
-15% -$740K 0.1% 156
2014
Q4
$4.67M Buy
67,732
+19,500
+40% +$1.32M 0.1% 149
2014
Q3
$3.13M Buy
48,232
+31,400
+187% +$1.99M 0.07% 214
2014
Q2
$1.05M Sell
16,832
-39,820
-70% -$2.38M 0.03% 482
2014
Q1
$3.33M Sell
56,652
-24,100
-30% -$1.34M 0.1% 186
2013
Q4
$4.12M Sell
80,752
-43,200
-35% -$2.16M 0.17% 135
2013
Q3
$6.24M Sell
123,952
-21,300
-15% -$1.12M 0.27% 82
2013
Q2
$7.13M Buy
+145,252
New +$7.9M 0.32% 66

Other funds holding LLY

Barings's LLY Position: Q1 2026 in Review

Barings reduced its Eli Lilly (LLY) stake by 38% in Q1 2026, selling an estimated $713K and leaving 1,162 shares worth $1.07M. The position accounts for 0.02% of the portfolio, ranked #136.

Barings first reported a position in LLY in Q2 2013 and has held it in 50 quarters since. The position peaked at $10.2M in Q4 2019. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Barings held 1,162 shares of Eli Lilly worth $1.07M as of Q1 2026.
  • Barings sold 703 Eli Lilly shares in Q1 2026, an estimated $713K.
  • Eli Lilly made up 0.02% of Barings's portfolio in Q1 2026, its #136 holding.
  • Barings first reported a position in Eli Lilly in Q2 2013 and has held it in 50 quarters since.
  • Barings's Eli Lilly position peaked at $10.2M in Q4 2019.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Barings's 13F filing for Q1 2026, filed 6 May 2026.